Xencor Collaborates with Genentech for Novel Interleukin-15 Bispecific Antibodies
By Jasmine Kalsi & Michelle Liu
Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)
Published: 9 Feb-2019
DOI: 10.3833/pdr.v2019.i2.2405 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Just weeks after regaining rights to a bispecific antibody from Novartis, Xencor has entered into a research collaboration and license agreement with Genentech to develop and commercialise interleukin-15 (IL-15) therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS